公开(公告)号：US10576131B2

公开(公告)日：2020-03-03

申请号：US15569303

申请日：2016-06-03

Applicant: AFFIRIS AG

Inventor： Guenther Staffler ,  Dorian Winter

IPC: C07K14/54 ,  C07K7/06 ,  C07K7/08 ,  C07K9/00 ,  C07K17/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/20 ,  A61K39/00 ,  A61K38/16 ,  A61P37/00

Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, that includes a peptide bound to a pharmaceutically acceptable carrier, wherein the peptide is QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), or QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein the IL-23 related disease is one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, preferably M. Alzheimer or multiple sclerosis, atopic dermatitis, graft-versus-host disease, cancer, preferably Oesophagal carcinoma colorectal carcinoma, lung adenocarcinoma, small cell carcinoma, and squamous cell carcinoma of the oral cavity, especially psoriasis, neurodegenerative diseases or IBD.

公开(公告)号：US10570180B2

公开(公告)日：2020-02-25

申请号：US15570837

申请日：2016-05-06

Applicant: Norwegian University of Science and Technology (NTNU)

Inventor： Marit Otterlei ,  Siri Bachke

IPC: A01N37/18 ,  A61K38/00 ,  A61P31/04 ,  A61K38/08 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/00 ,  A61K38/17 ,  C07K14/47 ,  A61K47/50 ,  A61L9/20 ,  A61L27/22 ,  C12N5/078

Abstract: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5X6 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an aromatic amino acid or a hydrophobic amino acid that has an R group comprising at least three carbon atoms; X4 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X5 is any amino acid other than an acidic amino acid or an aromatic amino acid; and X6 is any amino acid other than an acidic amino acid or an aromatic amino acid, preferably a basic amino acid or Proline (P), wherein when X3 is not an aromatic amino acid, X5 is not lysine (K) and X6 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and composition of the invention may be used as single agents. In other aspects of the invention the agents and composition may be used in conjunction with one or more addition active agents, such as antibiotics, or in combination with UV radiation.

公开(公告)号：US10519239B2

公开(公告)日：2019-12-31

申请号：US15576609

申请日：2016-05-25

Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： David Chatenet ,  Nicolas Doucet ,  Yves St-Pierre ,  Maria-Claudia Vladoiu

IPC: A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/00 ,  A61P35/00 ,  A61K38/10 ,  A61K38/16 ,  A61K38/08 ,  C07K16/28 ,  C07K7/06 ,  C07K7/08 ,  A61K38/17 ,  C07K14/47 ,  A61K39/395 ,  G01N33/531

Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.

公开(公告)号：US20190324030A1

公开(公告)日：2019-10-24

申请号：US16312956

申请日：2017-06-27

Applicant: Juno Therapeutics, Inc.

Inventor： Semih U. TAREEN ,  James SISSONS ,  Mark FROHLICH ,  Allen EBENS

IPC: G01N33/566 ,  C07K17/00 ,  G01N33/569 ,  C07K16/28 ,  G01N33/574 ,  C07K14/74

Abstract: Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen or pathogenic antigen. Also provided are methods of identifying peptide binding molecules that bind to a peptide in the context of an MHC-E molecule. In some embodiments, the peptide binding molecule is a T cell receptor (TCR) or antibody, including antigen-binding fragments thereof and chimeric antigen receptors (CAR) thereof. Also provided are methods of genetically engineering cells containing such MHC-E-restricted peptide binding molecules, and such genetically engineered cells, including compositions thereof and uses in adoptive cell therapy.

公开(公告)号：US10442834B2

公开(公告)日：2019-10-15

申请号：US14873517

申请日：2015-10-02

Applicant: AJINOMOTO CO., INC.

Inventor： Hironao Sajiki ,  Yasunari Monguchi

IPC: A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K2/00 ,  C07K4/00 ,  C07K14/00 ,  A61K38/04 ,  A61K38/06 ,  C07K1/02 ,  C07C319/20 ,  C07C321/14 ,  C07C321/28 ,  C07C53/16 ,  C07K5/062 ,  C07K5/087 ,  C07K5/103

Abstract: The present invention provides a method of efficiently deprotecting a protected organic compound by catalytic hydrogenation. Specifically, the present invention provides a method of deprotecting an organic compound having at least one functional group selected from the group consisting of a carboxy group, an amino group and a hydroxy group, which is protected by a protecting group represented by the formula (I): R1—C(R2)(R3)-L1-  (I) [wherein R1 is an aryl group optionally having substituent(s), R2 and R3 are each independently, a hydrogen atom or an aryl group optionally having substituent(s), and L1 is a single bond, —O—CO— or —O—CH2—], comprising hydrogenation in the presence of a metal catalyst and halogenated acetic acid.

公开(公告)号：US10385120B2

公开(公告)日：2019-08-20

申请号：US13576083

申请日：2011-02-01

Applicant: Michel Leonetti ,  Alexandra Savatier ,  Adeline Gadzinski ,  Jean-Claude Boulain

Inventor： Michel Leonetti ,  Alexandra Savatier ,  Adeline Gadzinski ,  Jean-Claude Boulain

IPC: C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K16/18 ,  A61K39/39 ,  C07K16/28 ,  A61K47/64 ,  A61K47/68 ,  A61K39/00

Abstract: The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand.

公开(公告)号：US20190233475A1

公开(公告)日：2019-08-01

申请号：US16239264

申请日：2019-01-03

Applicant: BicycleRD Limited

Inventor： Daniel Teufel ,  Catherine Stace ,  Edward Walker

IPC: C07K7/64 ,  C07K17/00 ,  C07K7/08

CPC classification number: C07K7/64 ,  A61K38/00 ,  C07K7/08 ,  C07K17/00

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human and rat protease plasma kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.

公开(公告)号：US10322163B2

公开(公告)日：2019-06-18

申请号：US14884115

申请日：2015-10-15

Applicant: Cerenis Therapeutics Holding S.A.

Inventor： Jean-Louis Dasseux ,  Rose Ackermann ,  Daniela Carmen Oniciu

IPC: A23J1/00 ,  C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C09H1/04 ,  A61K38/00 ,  A61P3/06 ,  A61K38/16 ,  A61K38/17 ,  C07K1/04 ,  A61K45/00 ,  C07K14/775 ,  A61K38/18 ,  A61K47/50

Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.

公开(公告)号：US10294286B2

公开(公告)日：2019-05-21

申请号：US15400412

申请日：2017-01-06

Applicant: Rigshospitalet ,  Kobenhavns Universitet ,  Syddansk Universitet

Inventor： Peter Garred ,  Tina Hummelshoj Glue ,  Mikkel-Ole Skjodt

IPC: A61K38/36 ,  A61K38/00 ,  A61P7/08 ,  A61K38/14 ,  A61K35/14 ,  A61K38/16 ,  C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C12P21/08 ,  C07K14/47 ,  A61K38/17 ,  A61K45/06 ,  C07K14/705 ,  C07K14/81

Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

公开(公告)号：US10294285B2

公开(公告)日：2019-05-21

申请号：US15212277

申请日：2016-07-17

Applicant: Therabron Therapeutics, Inc.

Inventor： Aprile L. Pilon-Clayton ,  Humcha K. Hariprakasha ,  Richard S. Clayton ,  Melissa E. Winn

IPC: A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/47 ,  A61K38/17 ,  C12P21/00

Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.